Smart Money Is Buying Avantor Inc (AVTR)

According to the most recent reported 13F filings, institutional investors showed renewed buying interest in Avantor Inc (AVTR), with several prominent hedge funds, quantitative managers, and long-term value investors increasing exposure or initiating new positions during the quarter. The accumulation comes as investors evaluate Avantor’s position as a leading supplier of products and services to the life sciences, healthcare, and advanced technology industries, while management continues to focus on operational improvements and margin expansion.

Below are the most notable buyers from the latest reported quarter:

Ed Wachenheim – Greenhaven Associates Inc

Shares: 22,593,838  Change: +2,093,185  Value: $0.18B

Ed Wachenheim’s Greenhaven Associates recorded the largest increase among tracked investors, adding more than 2 million shares during the quarter. The sizeable addition further strengthens Greenhaven’s already significant position and reflects continued conviction in Avantor’s long-term value and earnings recovery potential.

---

Joel Greenblatt – Gotham Asset Management, LLC

Shares: 1,328,179  Change: +965,823  Value: $0.01B

Joel Greenblatt’s Gotham Asset Management made a substantial addition to its Avantor position, nearly tripling its holdings during the quarter. The increase suggests Gotham sees attractive valuation characteristics and favorable risk-reward potential following recent share price weakness.

---

Cliff Asness – AQR Capital Management LLC

Shares: 4,867,208  Change: +475,611  Value: $0.04B

AQR Capital Management expanded its Avantor stake by nearly half a million shares. The addition reflects continued interest from quantitative investors who may view the company’s valuation, profitability, and market position favorably relative to peers.

---

Rob Olstein – Olstein Capital Management, L.P.

Shares: 1,210,000  Change: +392,000  Value: $0.01B

Rob Olstein increased his firm’s Avantor position by approximately 48% during the quarter. The purchase is consistent with Olstein’s value-oriented approach of seeking companies trading below intrinsic value with opportunities for operational improvement.

---

Donald Yacktman – Yacktman Asset Management LP

Shares: 4,745,000  New Position  Value: $0.04B

Donald Yacktman established a significant new position in Avantor during the quarter. Given Yacktman’s reputation for investing in high-quality businesses at attractive valuations, the sizeable new stake represents a notable endorsement of the company’s long-term prospects.

---

Ray Dalio – Bridgewater Associates, LP

Shares: 128,209  New Position  Value: $0.00B

Bridgewater initiated a new position in Avantor during the quarter. While modest in size, the addition places the company on the radar of one of the world’s largest hedge funds and reflects growing institutional interest.

---

Jeremy Grantham – Grantham, Mayo, Van Otterloo & Co. LLC

Shares: 106,700  New Position  Value: $0.00B

Jeremy Grantham’s GMO also established a new position in Avantor. Although relatively small, the investment suggests GMO sees value in the shares following the company’s recent underperformance and improving long-term fundamentals.

---

Lee Ainslie – Maverick Capital Ltd

Shares: 100,814  New Position  Value: $0.00B

Lee Ainslie initiated a new position in Avantor during the quarter. The purchase adds another respected fundamental investor to the shareholder base and may reflect optimism regarding the company’s recovery potential and market position within the life sciences supply chain.

---

Overall Takeaway

Collectively, these filings highlight broad-based institutional accumulation of Avantor shares. The largest additions came from Ed Wachenheim’s Greenhaven Associates, Joel Greenblatt’s Gotham Asset Management, AQR Capital Management, and Olstein Capital Management, while Donald Yacktman, Ray Dalio, Jeremy Grantham, and Lee Ainslie all initiated new positions.

The combination of buying from value-oriented managers, quantitative firms, and long-term fundamental investors suggests growing confidence that Avantor may be undervalued relative to its long-term earnings potential. As the company continues to serve critical life sciences and healthcare markets while focusing on operational execution and margin improvement, AVTR appears to be attracting increased attention from sophisticated institutional investors.